

**BUY** Century Plyboards

## In-line quarter; maintain outlook

Building Materials ▶ Result Update ▶ November 10, 2023

TARGET PRICE (Rs): 820

**Century Ply's Q2FY24 standalone EBITDA declined 7% YoY/increased 8% QoQ to Rs1.4bn, in line with our estimates. EBITDA margin slipped by 253bps YoY/54bps QoQ to 14.2%. Regarding MDF, with stabilization of the second line at Hoshiarpur, the management revised its H2FY24 growth target from 20% to 25%, given that margin is likely to remain stable/improve. The ongoing MDF & Laminates project at AP is on track for commissioning in FY24. We broadly maintain FY24E-26E EBITDA/EPS and revise Sep-24E TP to Rs820/share, post quarterly rollover, based on 32x P/E. Overall, we expect EBITDA/EPS CAGR of 19-21% over FY23-26E. We maintain our BUY rating on Century Ply, as we like its integrated business model, leadership position, strong branding and higher growth visibility, underpinned by expansion plans and a robust balance sheet.**

**Century Plyboards: Financial Snapshot (Consolidated)**

Y/E Mar (Rs mn)	FY22	FY23	FY24E	FY25E	FY26E
Revenue	30,270	36,466	39,777	47,162	56,136
EBITDA	5,308	5,587	6,168	7,844	9,862
Adj. PAT	3,131	3,833	3,931	4,947	6,455
Adj. EPS (Rs)	14.1	17.3	17.7	22.3	29.1
EBITDA margin (%)	17.5	15.3	15.5	16.6	17.6
EBITDA growth (%)	58.2	5.2	10.4	27.2	25.7
Adj. EPS growth (%)	63.5	22.4	2.6	25.8	30.5
RoE (%)	22.2	22.1	18.8	20.0	21.7
RoIC (%)	35.6	30.5	24.3	23.9	27.1
P/E (x)	45.3	37.0	36.1	28.7	22.0
EV/EBITDA (x)	26.7	25.4	24.0	18.9	14.9
P/B (x)	9.1	7.4	6.3	5.3	4.4
FCFF yield (%)	0.1	(0.3)	(3.8)	0.4	1.3

Source: Company, Emkay Research

**Result Summary:** Century's Plywood EBITDA increased 7% YoY/10% QoQ to Rs730mn with EBITDA margin decline of 48bps YoY/flat QoQ, at 13.6%. Volume grew 8% YoY to 94K CBM. MDF segment EBITDA increased 32% YoY/19% QoQ to Rs521mn (including arrears in electric subsidy of Rs78mn). Adjusting for the same, EBITDA margin declined by 180bps YoY/268bps QoQ to 23.5%. MDF volume grew 19% YoY/12% QoQ to 54K CBM. EBITDA for Laminates declined 34% YoY/rose 28% QoQ to Rs201mn, with margin decline of 557bps YoY/gain of 167bps QoQ, to 11.8%. Particle-Board EBITDA declined 36% YoY/3% QoQ to Rs87mn, with margin falling by 595bps YoY/staying flat QoQ, at 22%. Consolidated FCF generation stood at a negative Rs3.6bn, post working-capital blockage of Rs1.5bn and capex spend of Rs4.4bn in H1FY24.

**What we like:** Upward revision in growth guidance of the MDF segment

**What we do not like:** Lower than expected volumes in laminate segment


**Key Concall Takeaways:** i) In plywood, Company maintains guidance of overall 10% revenue growth and EBITDA margin sustain at 13-14% in H2FY24. ii) In laminates, Company has introduced Sainik Laminates in the economy market. With introduction of new ranges that target specific new market segments, overall performance of the laminates division will improve in coming quarters. The management has guided for QoQ double-digit growth and improving EBITDA margin. iii) With the second line at Hoshiarpur now stabilized, the management has revised up its growth target, from 20% to 25% for H2FY24. With increase in share of premium products, margin is likely to remain stable or improve in coming quarters. iv) In Particle Boards, the management expects improvement in both, revenue and margin, in the next few quarters. v) The ongoing MDF and Laminates project at Andhra Pradesh is on track and will commence operations in FY24. vi) Capex-spend in H1FY24 stood at Rs4.6bn and the management has guided for capex of Rs5.7bn and Rs4.5bn for H2FY24 and FY25, respectively.

Target Price – 12M	Sep-24
<b>Change in TP (%)</b>	<b>5.1</b>
Current Reco.	BUY
Previous Reco.	BUY
Upside/(Downside) (%)	28.5
CMP (09-Nov-23) (Rs)	638.0

Stock Data	Ticker
52-week High (Rs)	722
52-week Low (Rs)	436
Shares outstanding (mn)	222.2
Market-cap (Rs bn)	142
Market-cap (USD mn)	1,702
Net-debt, FY24E (Rs mn)	6,293
ADTV-3M (mn shares)	-
ADTV-3M (Rs mn)	94.3
ADTV-3M (USD mn)	1.1
Free float (%)	-
Nifty-50	19,395
INR/USD	83.3
<b>Shareholding, Sep-23</b>	
Promoters (%)	73.0
FPIs/MFs (%)	5.6/14.5

**Price Performance**

(%)	1M	3M	12M
Absolute	(0.3)	1.9	8.8
Rel. to Nifty	0.3	3.1	1.8

**1-Year share price trend (Rs)****Dharmesh Shah**

dharmesh.shah@emkayglobal.com  
+91 22 6612 1255

**Cheragh Sidhwa**

cheragh.sidhwa@emkayglobal.com  
+91 22 6612 1219

## Quarterly Analysis

### Exhibit 1: Actual vs. Estimates (Q2FY24)

(Rs mn)	Actual	Estimates		Variation (%)		Comment
		Emkay	Consensus	Emkay	Consensus	
Net sales	9,879	9,360	9,421	5.5	4.9	
<b>EBITDA</b>	<b>1,404</b>	<b>1,444</b>	<b>1,442</b>	<b>(2.8)</b>	<b>(2.6)</b>	<b>In line with estimates</b>
EBITDA margin (%)	14.2	15.4	15.3			
PAT	903	943	957	(4.2)	(5.6)	

Source: Bloomberg, Emkay Research

### Exhibit 2: Quarterly Analysis – Standalone

(Rs mn)	Q2FY23	Q3FY23	Q4FY23	Q1FY24	Q2FY24	YoY (%)	QoQ (%)	H1FY23	H1FY24	YoY (%)
<b>Revenue</b>	<b>9,002</b>	<b>8,772</b>	<b>9,618</b>	<b>8,824</b>	<b>9,879</b>	<b>9.7</b>	<b>12.0</b>	<b>17,817</b>	<b>18,703</b>	<b>5.0</b>
<b>Expenditure</b>	<b>7,495</b>	<b>7,498</b>	<b>7,991</b>	<b>7,522</b>	<b>8,475</b>	<b>13.1</b>	<b>12.7</b>	<b>14,857</b>	<b>15,997</b>	<b>7.7</b>
Total RM cost	4,882	4,788	5,095	4,645	5,199	6.5	11.9	9,539	9,844	3.2
Staff cost	1,138	1,089	1,196	1,270	1,300	14.2	2.3	2,290	2,569	12.2
Other expenditure	1,475	1,622	1,700	1,608	1,977	34.0	23.0	3,028	3,584	18.4
<b>EBITDA</b>	<b>1,507</b>	<b>1,274</b>	<b>1,627</b>	<b>1,302</b>	<b>1,404</b>	<b>(6.8)</b>	<b>7.8</b>	<b>2,960</b>	<b>2,706</b>	<b>(8.6)</b>
Depreciation	178	180	187	218	221	24.1	1.2	356	439	23.3
<b>EBIT</b>	<b>1,329</b>	<b>1,094</b>	<b>1,440</b>	<b>1,083</b>	<b>1,183</b>	<b>(11.0)</b>	<b>9.2</b>	<b>2,603</b>	<b>2,266</b>	<b>(12.9)</b>
Other Income	195	61	136	99	88	(55.0)	(11.5)	255	187	(26.7)
Interest	34	40	41	57	57	65.2	0.2	73	114	55.3
<b>PBT</b>	<b>1,489</b>	<b>1,115</b>	<b>1,535</b>	<b>1,126</b>	<b>1,214</b>	<b>(18.5)</b>	<b>7.8</b>	<b>2,785</b>	<b>2,339</b>	<b>(16.0)</b>
Total Tax	257	277	407	285	310	20.7	9.0	588	595	1.2
<b>Adjusted PAT</b>	<b>1,232</b>	<b>837</b>	<b>1,128</b>	<b>841</b>	<b>903</b>	<b>(26.7)</b>	<b>7.4</b>	<b>2,197</b>	<b>1,744</b>	<b>(20.6)</b>
(Profit)/loss from JVs/Assoc./MI	470	24	-	-	-			470	-	
PAT after MI	762	814	1,128	841	903	18.5	7.4	1,727	1,744	1.0
Extra ordinary items	-	-	-	-	-			-	-	
<b>Reported PAT</b>	<b>762</b>	<b>814</b>	<b>1,128</b>	<b>841</b>	<b>903</b>	<b>18.5</b>	<b>7.4</b>	<b>1,727</b>	<b>1,744</b>	<b>1.0</b>
<b>Adjusted EPS (Rs)</b>	<b>5.5</b>	<b>3.8</b>	<b>5.1</b>	<b>3.8</b>	<b>4.1</b>	<b>(26.7)</b>	<b>7.4</b>	<b>9.9</b>	<b>7.8</b>	<b>(20.6)</b>
(%)	Q2FY23	Q3FY23	Q4FY23	Q1FY24	Q2FY24	YoY (bps)	QoQ (bps)	H1FY23	H1FY24	YoY (bps)
<b>EBITDAM</b>	<b>16.7</b>	<b>14.5</b>	<b>16.9</b>	<b>14.8</b>	<b>14.2</b>	<b>(253)</b>	<b>(54)</b>	<b>16.6</b>	<b>14.5</b>	<b>(215)</b>
EBITM	14.8	12.5	15.0	12.3	12.0	(279)	(30)	14.6	12.1	(249)
EBTM	16.5	12.7	16.0	12.8	12.3	(426)	(47)	15.6	12.5	(312)
PATM	13.7	9.5	11.7	9.5	9.1	(454)	(39)	12.3	9.3	(300)
Effective Tax rate	17.3	24.9	26.5	25.3	25.6			21.1	25.4	

Source: Company, Emkay Research

## Exhibit 3: Segmental Performance

MDF	Q2FY23	Q3FY23	Q4FY23	Q1FY24	Q2FY24	YoY (%)	QoQ (%)	H1FY23	H1FY24	YoY (%)
Sales Volumes (K CBM)	45,109	48,099	46,801	47,988	53,724	19.1	12.0	90,418	1,01,712	12.5
<b>Realization (Rs/CBM)</b>	<b>34,649</b>	<b>34,392</b>	<b>34,294</b>	<b>34,752</b>	<b>35,118</b>	<b>1.4</b>	<b>1.1</b>	<b>34,472</b>	<b>34,946</b>	<b>1.4</b>
Net sales (Rs mn)	1,563	1,654	1,605	1,668	1,887	20.7	13.1	3,117	3,554	14.0
<b>EBITDA (Rs mn)</b>	<b>395</b>	<b>373</b>	<b>435</b>	<b>437</b>	<b>521</b>	<b>31.7</b>	<b>19.3</b>	<b>938</b>	<b>957</b>	<b>2.0</b>
EBITDA margin (%)	25.3	22.6	27.1	26.2	27.6			30.1	26.9	
<b>EBITDA/CBM (Rs)</b>	<b>8,763</b>	<b>7,759</b>	<b>9,297</b>	<b>9,096</b>	<b>9,692</b>	<b>10.6</b>	<b>6.6</b>	<b>10,378</b>	<b>9,411</b>	<b>(9.3)</b>
Plywood	Q2FY23	Q3FY23	Q4FY23	Q1FY24	Q2FY24	YoY (%)	QoQ (%)	H1FY23	H1FY24	YoY (%)
Sales Volumes (CBM)	87,547	87,606	98,273	87,869	94,361	7.8	7.4	1,75,562	1,82,230	3.8
<b>Realization (Rs/CBM)</b>	<b>55,465</b>	<b>54,945</b>	<b>57,640</b>	<b>55,476</b>	<b>57,121</b>	<b>3.0</b>	<b>3.0</b>	<b>54,631</b>	<b>56,328</b>	<b>3.1</b>
Net sales (Rs mn)	4,856	4,814	5,665	4,875	5,390	11.0	10.6	9,591	10,265	7.0
<b>EBITDA (Rs mn)</b>	<b>681</b>	<b>565</b>	<b>904</b>	<b>666</b>	<b>730</b>	<b>7.2</b>	<b>9.7</b>	<b>1,176</b>	<b>1,397</b>	<b>18.7</b>
EBITDA margin (%)	14.0	11.7	16.0	13.7	13.6			12.3	13.6	
Laminates	Q2FY23	Q3FY23	Q4FY23	Q1FY24	Q2FY24	YoY (%)	QoQ (%)	H1FY23	H1FY24	YoY (%)
Sales Volumes (mn sheets)	1.9	1.6	1.8	1.8	2.0	6.7	12.0	3.8	3.9	3.2
<b>Realization (Rs/sheet)</b>	<b>908</b>	<b>954</b>	<b>904</b>	<b>846</b>	<b>832</b>	<b>(8.4)</b>	<b>(1.7)</b>	<b>895</b>	<b>839</b>	<b>(6.3)</b>
Net sales (Rs mn)	1,740	1,563	1,590	1,547	1,702	(2.2)	10.0	3,360	3,249	(3.3)
<b>EBITDA (Rs mn)</b>	<b>306</b>	<b>225</b>	<b>226</b>	<b>157</b>	<b>201</b>	<b>(34.4)</b>	<b>28.2</b>	<b>524</b>	<b>357</b>	<b>(31.9)</b>
EBITDA margin (%)	17.6	14.4	14.2	10.1	11.8			15.6	11.0	
Particle Board	Q2FY23	Q3FY23	Q4FY23	Q1FY24	Q2FY24	YoY (%)	QoQ (%)	H1FY23	H1FY24	YoY (%)
Sales Volumes (CBM)	19,157	15,595	16,733	19,040	18,350	(4.2)	(3.6)	40,694.0	37,390.0	(8.1)
<b>Realization (Rs/CBM)</b>	<b>24,675</b>	<b>24,649</b>	<b>22,243</b>	<b>20,725</b>	<b>20,894</b>	<b>(15.3)</b>	<b>0.8</b>	<b>24,166</b>	<b>20,808</b>	<b>(13.9)</b>
Net sales (Rs mn)	473	384	372	395	383	(18.9)	(2.8)	983	778	(20.9)
<b>EBITDA (Rs mn)</b>	<b>135</b>	<b>79</b>	<b>67</b>	<b>90</b>	<b>87</b>	<b>(35.8)</b>	<b>(3.3)</b>	<b>319</b>	<b>176</b>	<b>(44.8)</b>
EBITDA margin (%)	28.5	20.4	18.1	22.7	22.6			32.4	22.6	

Source: Company, Emkay Research

## Exhibit 4: Quarterly Analysis – Consolidated

(Rs mn)	Q2FY23	Q3FY23	Q4FY23	Q1FY24	Q2FY24	YoY (%)	QoQ (%)	H1FY23	H1FY24	YoY (%)
<b>Revenue</b>	<b>9,086</b>	<b>8,837</b>	<b>9,654</b>	<b>8,910</b>	<b>9,968</b>	<b>9.7</b>	<b>11.9</b>	<b>17,974</b>	<b>18,878</b>	<b>5.0</b>
<b>Expenditure</b>	<b>7,856</b>	<b>7,551</b>	<b>8,016</b>	<b>7,578</b>	<b>8,525</b>	<b>8.5</b>	<b>12.5</b>	<b>15,312</b>	<b>16,104</b>	<b>5.2</b>
Total RM cost	4,850	4,703	5,002	4,601	5,142	6.0	11.8	9,457	9,743	3.0
Staff cost	1,191	1,127	1,239	1,310	1,343	12.7	2.5	2,384	2,653	11.3
Other expenditure	1,815	1,721	1,775	1,667	2,040	12.4	22.3	3,472	3,707	6.8
<b>EBITDA</b>	<b>1,230</b>	<b>1,287</b>	<b>1,638</b>	<b>1,332</b>	<b>1,443</b>	<b>17.3</b>	<b>8.3</b>	<b>2,662</b>	<b>2,775</b>	<b>4.2</b>
Depreciation	191	193	200	231	234	22.4	1.2	382	464	21.7
<b>EBIT</b>	<b>1,039</b>	<b>1,093</b>	<b>1,438</b>	<b>1,101</b>	<b>1,209</b>	<b>16.4</b>	<b>9.8</b>	<b>2,280</b>	<b>2,310</b>	<b>1.3</b>
Other Income	204	53	160	122	146	(28.4)	20.0	264	267	1.4
Interest	38	44	45	61	61	60.0	(0.0)	81	123	51.6
<b>PBT</b>	<b>1,205</b>	<b>1,102</b>	<b>1,554</b>	<b>1,161</b>	<b>1,294</b>	<b>7.4</b>	<b>11.4</b>	<b>2,463</b>	<b>2,455</b>	<b>(0.3)</b>
Total Tax	260	279	408	290	322	24.1	11.3	592	612	3.5
<b>Adjusted PAT</b>	<b>945</b>	<b>824</b>	<b>1,146</b>	<b>871</b>	<b>971</b>	<b>2.8</b>	<b>11.5</b>	<b>1,871</b>	<b>1,842</b>	<b>(1.5)</b>
(Profit)/loss from JVs/Assoc./MI	(4)	(1)	(1)	(2)	(3)	(35)	30	(7)	(5)	(34.8)
PAT after MI	941	822	1,145	869	969	3.0	11.4	1,864	1,838	(1.4)
Extra ordinary items	-	-	-	-	-					
<b>Reported PAT</b>	<b>941</b>	<b>822</b>	<b>1,145</b>	<b>869</b>	<b>969</b>	<b>3.0</b>	<b>11.4</b>	<b>1,864</b>	<b>1,838</b>	<b>(1.4)</b>
<b>Adjusted EPS (Rs)</b>	<b>4.2</b>	<b>3.7</b>	<b>5.1</b>	<b>3.9</b>	<b>4.4</b>	<b>3.0</b>	<b>11.4</b>	<b>8.4</b>	<b>8.3</b>	<b>(1.4)</b>
(%)	Q1FY23	Q2FY23	Q3FY23	Q4FY23	Q1FY24	Q2FY24	YoY (bps)	QoQ (bps)	H1FY23	H1FY24
<b>EBITDAM</b>	<b>16.1</b>	<b>13.5</b>	<b>14.6</b>	<b>17.0</b>	<b>14.9</b>	<b>14.5</b>	<b>93</b>	<b>(47)</b>	<b>14.8</b>	<b>14.7</b>
EBITM	14.0	11.4	12.4	14.9	12.4	12.1	69	(23)	12.7	12.2
EBTM	14.2	13.3	12.5	16.1	13.0	13.0	(28)	(5)	13.7	13.0
PATM	10.4	10.4	9.3	11.9	9.8	9.7	(66)	(4)	10.4	9.8
Effective Tax rate	26.4	21.6	25.3	26.2	25.0	24.9			24.0	24.9

Source: Company, Emkay Research

## Exhibit 5: Key assumptions

Segmental performance (Rs bn)	FY18	FY19	FY20	FY21	FY22	FY23	FY24E	FY25E	FY26E	CAGR (%)	
										FY18-23	FY23-26E
<b>Plywood</b>											
Sales volumes ('000 CBM)	254	253	244	223	298	361	382	430	460	7.3	8.3
YoY (%)	0.9	(0.5)	(3.3)	(8.8)	33.9	21.3	5.7	12.6	6.8		
Revenue	12.6	12.7	12.3	11.2	15.8	20.1	21.9	24.6	26.5	9.7	9.8
YoY (%)	0.2	0.8	(3.3)	(9.0)	41.0	27.1	8.9	12.8	7.7		
<b>EBITDA</b>	<b>1.8</b>	<b>1.7</b>	<b>1.1</b>	<b>1.2</b>	<b>2.2</b>	<b>2.2</b>	<b>3.0</b>	<b>3.4</b>	<b>3.7</b>	<b>3.7</b>	<b>19.9</b>
YoY (%)	(16.3)	(3.7)	(35.6)	7.9	84.4	(2.7)	37.0	14.8	9.6		
Margin (%)	14.3	13.7	9.1	10.8	14.1	10.8	13.6	13.9	14.1	-351bps	329bps
<b>Laminates</b>											
Sales volumes (mn sheets)	5.42	5.88	6.19	5.52	6.75	7.21	7.90	9.00	10.45	5.9	13.2
YoY (%)	(7.1)	8.4	5.3	(10.9)	22.3	6.8	9.6	14.0	16.0		
Revenue	3.7	4.3	4.5	4.1	5.7	6.5	6.8	7.9	9.4	12.0	13.0
YoY (%)	1.8	16.8	5.2	(10.3)	39.0	14.8	4.3	16.6	18.6		
<b>EBITDA</b>	<b>0.6</b>	<b>0.4</b>	<b>0.6</b>	<b>0.7</b>	<b>0.9</b>	<b>1.0</b>	<b>0.8</b>	<b>1.0</b>	<b>1.2</b>	<b>10.4</b>	<b>8.3</b>
YoY (%)	1.7	(35.2)	62.3	18.4	21.8	8.0	(19.0)	26.5	24.0		
Margin (%)	16.1	8.9	13.8	18.2	15.9	15.0	11.6	12.6	13.2	-113bps	-178bps
<b>MDF</b>											
Sales volumes ('000 CBM)	48	132	153	147	178	185	221	324	428	30.9	32.2
YoY (%)	NA	173.7	15.8	(3.9)	20.8	4.1	19.0	47.0	32.0		
Revenue	1.1	3.0	3.5	3.6	5.6	6.4	7.7	11.2	14.9	41.4	32.8
YoY (%)	NA	161.6	18.7	2.5	54.6	14.8	20.2	45.5	34.0		
<b>EBITDA</b>	<b>0.2</b>	<b>0.4</b>	<b>0.9</b>	<b>0.9</b>	<b>1.8</b>	<b>1.7</b>	<b>2.0</b>	<b>2.8</b>	<b>3.8</b>	<b>52.4</b>	<b>29.7</b>
YoY (%)	NA	80.3	126.2	7.0	91.6	(1.8)	11.7	44.4	35.2		
Margin (%)	18.9	13.0	24.8	25.8	32.0	27.4	25.5	25.3	25.5	854bps	-190bps
<b>Rs/CBM</b>	<b>4,403</b>	<b>2,900</b>	<b>5,662</b>	<b>6,302</b>	<b>9,992</b>	<b>9,426</b>	<b>8,845</b>	<b>8,689</b>	<b>8,902</b>	<b>16.4</b>	<b>(1.9)</b>
<b>Particle Board</b>											
Sales volumes ('000 CBM)	46.0	61.9	62.7	55.0	72.9	73.0	74.3	75.0	157.5	9.7	29.2
YoY (%)	135.7	34.6	1.4	(12.4)	32.7	0.1	1.7	1.0	110.0		
Revenue	0.7	1.0	1.0	0.9	1.5	1.7	1.6	1.6	3.4	19.0	24.7
YoY (%)	215.3	33.6	1.7	(9.1)	67.1	15.6	(10.4)	2.0	112.1		
<b>EBITDA</b>	<b>0.1</b>	<b>0.2</b>	<b>0.2</b>	<b>0.2</b>	<b>0.4</b>	<b>0.5</b>	<b>0.4</b>	<b>0.4</b>	<b>0.8</b>	<b>27.4</b>	<b>18.3</b>
YoY (%)	168.6	57.9	10.0	(24.9)	125.5	14.1	(23.5)	(0.2)	116.9		
Margin (%)	19.0	22.5	24.3	20.1	27.1	26.7	22.8	22.3	22.8	772bps	-390bps
<b>Rs/CBM</b>	<b>3,014</b>	<b>3,537</b>	<b>3,836</b>	<b>3,289</b>	<b>5,590</b>	<b>6,368</b>	<b>4,793</b>	<b>4,735</b>	<b>4,889</b>	<b>16.1</b>	<b>(8.4)</b>

Source: Company, Emkay Research

## Exhibit 6: Annual Analysis

Consolidated	FY18	FY19	FY20	FY21	FY22	FY23	FY24E	FY25E	FY26E	CAGR (%)	
										FY18-23	FY23-26E
<b>P&amp;L (Rs bn)</b>											
Revenue	20	23	23	21	30	36	40	47	56	12.5	15.5
<b>EBITDA</b>	<b>3.3</b>	<b>3.0</b>	<b>2.8</b>	<b>3.4</b>	<b>5.3</b>	<b>5.6</b>	<b>6.2</b>	<b>7.8</b>	<b>9.9</b>	<b>11.0</b>	<b>20.9</b>
Adj. Net Profit	1.6	1.5	1.5	2.0	3.1	3.8	3.9	4.9	6.5	18.6	19.0
<b>Balance Sheet (Rs bn)</b>											
Equity	8.5	9.7	10.9	12.7	15.6	19.1	22.6	26.9	32.5		
<b>Net Debt</b>	<b>5.5</b>	<b>5.0</b>	<b>2.4</b>	<b>-0.6</b>	<b>-0.2</b>	<b>0.4</b>	<b>6.3</b>	<b>6.3</b>	<b>5.0</b>		
Net Debt:EBITDA (x)	1.7	1.7	0.9	(0.2)	(0.0)	0.1	1.0	0.8	0.5		
Net Debt:Equity (x)	0.6	0.5	0.2	0.0	0.0	0.0	0.3	0.2	0.2		
<b>Cash Flow (Rs bn)</b>											
OCF before NWC change	2.5	2.4	2.8	2.8	4.3	4.9	4.9	6.1	7.8		
Change in NWC	0.2	(0.1)	0.8	0.8	(1.6)	(0.5)	0.1	(0.5)	(0.8)		
Capex	(2.4)	(1.6)	(0.2)	(0.5)	(2.6)	(4.8)	(10.5)	(5.1)	(5.1)		
<b>FCF</b>	<b>0.3</b>	<b>0.7</b>	<b>3.4</b>	<b>3.1</b>	<b>0.1</b>	<b>(0.4)</b>	<b>(5.6)</b>	<b>0.5</b>	<b>1.9</b>		
<b>Return ratios (%)</b>											
RoE	20.8	16.3	14.6	17.2	22.2	22.1	18.8	20.0	21.7		
RoCE	13.7	12.3	12.2	15.1	19.7	19.4	15.6	16.1	18.5		
<b>RoIC</b>	<b>13.5</b>	<b>13.3</b>	<b>12.7</b>	<b>15.7</b>	<b>22.8</b>	<b>19.7</b>	<b>15.7</b>	<b>15.4</b>	<b>17.4</b>		
<b>Valuations (x)</b>											
PER						37.0	36.1	28.7	22.0		
<b>EV/EBITDA</b>						<b>25.3</b>	<b>23.0</b>	<b>18.9</b>	<b>15.0</b>		
P/B						7.4	6.3	5.3	4.4		

Source: Company, Emkay Research

## Exhibit 7: We maintain BUY, with TP of Rs820/share, based on 32x Sep-25E P/E

	Rs/share
Sep-25E EPS	26
P/E (x)	32
<b>Target Price</b>	<b>820</b>
CMP	638
<b>Upside (%)</b>	<b>29</b>


Source: Company, Emkay Research

## Exhibit 8: We broadly maintain our estimates for FY24-26

(Rs mn)	FY24E			FY25E			FY26E		
	Old	New	Chg. (%)	Old	New	Chg. (%)	Old	New	Chg. (%)
Revenue	40,224	39,777	(1.1)	48,440	47,162	(2.6)	58,218	56,136	(3.6)
EBITDA	6,101	6,168	1.1	7,888	7,844	(0.6)	10,157	9,862	(2.9)
PAT	3,837	3,931	2.5	4,992	4,947	(0.9)	6,746	6,455	(4.3)


Source: Emkay Research

## Exhibit 9: One-year forward P/E



Source: Bloomberg, Emkay Research

## Exhibit 10: One-year forward EV/EBITDA



Source: Bloomberg, Emkay Research

## Century Plyboards: Consolidated Financials and Valuations

Profit & Loss					
Y/E Mar (Rs mn)	FY22	FY23	FY24E	FY25E	FY26E
<b>Revenue</b>	<b>30,270</b>	<b>36,466</b>	<b>39,777</b>	<b>47,162</b>	<b>56,136</b>
Revenue growth (%)	42.1	20.5	9.1	18.6	19.0
<b>EBITDA</b>	<b>5,308</b>	<b>5,587</b>	<b>6,168</b>	<b>7,844</b>	<b>9,862</b>
EBITDA growth (%)	58.2	5.2	10.4	27.2	25.7
Depreciation & Amortization	743	775	967	1,233	1,404
<b>EBIT</b>	<b>4,566</b>	<b>4,812</b>	<b>5,201</b>	<b>6,611</b>	<b>8,458</b>
EBIT growth (%)	71.1	5.4	8.1	27.1	27.9
Other operating income	0	0	0	0	0
Other income	231	477	377	341	323
Financial expense	114	170	302	334	229
<b>PBT</b>	<b>4,682</b>	<b>5,119</b>	<b>5,276</b>	<b>6,618</b>	<b>8,553</b>
Extraordinary items	0	0	0	0	0
Taxes	1,550	1,278	1,337	1,664	2,090
Minority interest	1	8	8	8	8
Income from JV/Associates	0	0	0	0	0
<b>Reported PAT</b>	<b>3,131</b>	<b>3,833</b>	<b>3,931</b>	<b>4,947</b>	<b>6,455</b>
PAT growth (%)	63.5	22.4	2.6	25.8	30.5
<b>Adjusted PAT</b>	<b>3,131</b>	<b>3,833</b>	<b>3,931</b>	<b>4,947</b>	<b>6,455</b>
<b>Diluted EPS (Rs)</b>	<b>14.1</b>	<b>17.3</b>	<b>17.7</b>	<b>22.3</b>	<b>29.1</b>
Diluted EPS growth (%)	63.5	22.4	2.6	25.8	30.5
<b>DPS (Rs)</b>	<b>1.5</b>	<b>1.0</b>	<b>1.7</b>	<b>2.2</b>	<b>2.8</b>
<b>Dividend payout (%)</b>	<b>10.7</b>	<b>5.8</b>	<b>9.8</b>	<b>9.7</b>	<b>9.7</b>
EBITDA margin (%)	17.5	15.3	15.5	16.6	17.6
EBIT margin (%)	15.1	13.2	13.1	14.0	15.1
Effective tax rate (%)	33.1	25.0	25.3	25.1	24.4
<b>NOPLAT (pre-IndAS)</b>	<b>3,054</b>	<b>3,610</b>	<b>3,883</b>	<b>4,949</b>	<b>6,391</b>
Shares outstanding (mn)	222.2	222.2	222.2	222.2	222.2

Source: Company, Emkay Research

Cash flows					
Y/E Mar (Rs mn)	FY22	FY23	FY24E	FY25E	FY26E
PBT	4,682	5,119	5,276	6,618	8,553
Others (non-cash items)	(62)	(86)	0	0	0
Taxes paid	(1,084)	(1,131)	(1,337)	(1,664)	(2,090)
Change in NWC	(1,632)	(467)	88	(546)	(783)
<b>Operating cash flow</b>	<b>2,762</b>	<b>4,379</b>	<b>4,919</b>	<b>5,634</b>	<b>6,989</b>
Capital expenditure	(2,576)	(4,830)	(10,498)	(5,051)	(5,051)
Acquisition of business	0	0	0	0	0
Interest & dividend income	35	212	377	341	323
<b>Investing cash flow</b>	<b>(3,199)</b>	<b>(4,796)</b>	<b>(10,121)</b>	<b>(4,711)</b>	<b>(4,728)</b>
Equity raised/(repaid)	0	0	0	0	0
Debt raised/(repaid)	737	915	4,500	(1,100)	(2,000)
Payment of lease liabilities	50	0	0	0	0
Interest paid	(116)	(144)	(302)	(334)	(229)
Dividend paid (incl tax)	(223)	(333)	(384)	(478)	(625)
Others	(50)	(49)	(53)	(82)	(100)
<b>Financing cash flow</b>	<b>349</b>	<b>388</b>	<b>3,761</b>	<b>(1,994)</b>	<b>(2,954)</b>
Net chg in Cash	(88)	(29)	(1,441)	(1,071)	(693)
OCF	2,762	4,379	4,919	5,634	6,989
Adj. OCF (w/o NWC chg.)	4,393	4,846	4,831	6,180	7,771
FCFF	186	(451)	(5,579)	582	1,937
FCFE	923	463	(1,079)	(518)	(63)
OCF/EBITDA (%)	52.0	78.4	79.8	71.8	70.9
FCFE/PAT (%)	29.5	12.1	(27.4)	(10.5)	(1.0)
<b>FCFF/NOPLAT (%)</b>	<b>6.1</b>	<b>(12.5)</b>	<b>(143.7)</b>	<b>11.8</b>	<b>30.3</b>

Source: Company, Emkay Research

Balance Sheet					
Y/E Mar (Rs mn)	FY22	FY23	FY24E	FY25E	FY26E
Share capital	223	223	223	223	223
Reserves & Surplus	15,346	18,921	22,381	26,682	32,307
<b>Net worth</b>	<b>15,568</b>	<b>19,143</b>	<b>22,604</b>	<b>26,905</b>	<b>32,530</b>
Minority interests	(26)	(37)	(37)	(37)	(37)
Deferred tax liability (net)	167	68	68	68	68
<b>Total debt</b>	<b>2,697</b>	<b>3,534</b>	<b>8,075</b>	<b>7,068</b>	<b>5,180</b>
<b>Total liabilities &amp; equity</b>	<b>18,406</b>	<b>22,708</b>	<b>30,709</b>	<b>34,003</b>	<b>37,741</b>
Net tangible fixed assets	7,748	10,673	18,505	22,673	24,321
Net intangible assets	20	17	17	17	17
Net ROU assets	0	0	0	0	0
Capital WIP	1,766	2,362	4,059	3,709	5,709
Goodwill	0	0	0	0	0
Investments [JV/Associates]	3	1	1	1	1
<b>Cash &amp; equivalents</b>	<b>2,610</b>	<b>2,782</b>	<b>1,341</b>	<b>270</b>	<b>(423)</b>
Current assets (ex-cash)	10,160	11,327	11,373	12,512	14,254
Current Liab. & Prov.	3,898	4,453	4,587	5,179	6,139
<b>NWC (ex-cash)</b>	<b>6,262</b>	<b>6,874</b>	<b>6,786</b>	<b>7,332</b>	<b>8,115</b>
<b>Total assets</b>	<b>18,406</b>	<b>22,708</b>	<b>30,709</b>	<b>34,003</b>	<b>37,741</b>
Net debt	(182)	352	6,293	6,264	4,957
Capital employed	18,138	22,308	30,268	33,470	37,095
<b>Invested capital</b>	<b>14,027</b>	<b>17,562</b>	<b>25,308</b>	<b>30,023</b>	<b>32,453</b>
BVPS (Rs)	70.1	86.2	101.7	121.1	146.4
Net Debt/Equity (x)	0.0	0.0	0.3	0.2	0.2
Net Debt/EBITDA (x)	0.0	0.1	1.0	0.8	0.5
Interest coverage (x)	42.0	31.1	18.5	20.8	38.4
<b>RoCE (%)</b>	<b>19.7</b>	<b>19.4</b>	<b>15.6</b>	<b>16.1</b>	<b>18.5</b>

Source: Company, Emkay Research

Valuations and key Ratios					
Y/E Mar	FY22	FY23	FY24E	FY25E	FY26E
P/E (x)	45.3	37.0	36.1	28.7	22.0
P/CE(x)	36.6	30.8	28.9	22.9	18.0
P/B (x)	9.1	7.4	6.3	5.3	4.4
EV/Sales (x)	4.7	3.9	3.7	3.1	2.6
EV/EBITDA (x)	26.7	25.4	24.0	18.9	14.9
EV/EBIT(x)	31.0	29.5	28.5	22.4	17.3
EV/IC (x)	10.1	8.1	5.8	4.9	4.5
FCFF yield (%)	0.1	(0.3)	(3.8)	0.4	1.3
FCFE yield (%)	0.7	0.3	(0.7)	(0.3)	0.0
Dividend yield (%)	0.2	0.2	0.3	0.3	0.4
<b>DuPont-RoE split</b>					
Net profit margin (%)	10.3	10.5	9.9	10.5	11.5
Total asset turnover (x)	1.9	1.8	1.5	1.5	1.6
Assets/Equity (x)	1.1	1.2	1.3	1.3	1.2
<b>RoE (%)</b>	<b>22.2</b>	<b>22.1</b>	<b>18.8</b>	<b>20.0</b>	<b>21.7</b>
<b>DuPont-RoIC</b>					
NOPLAT margin (%)	10.1	9.9	9.8	10.5	11.4
IC turnover (x)	2.4	2.3	1.9	1.7	1.8
<b>RoIC (%)</b>	<b>35.6</b>	<b>30.5</b>	<b>24.3</b>	<b>23.9</b>	<b>27.1</b>
<b>Operating metrics</b>					
Core NWC days	75.5	68.8	62.3	56.7	52.8
<b>Total NWC days</b>	<b>75.5</b>	<b>68.8</b>	<b>62.3</b>	<b>56.7</b>	<b>52.8</b>
Fixed asset turnover	2.7	2.7	2.0	1.8	1.8
Opex-to-revenue (%)	32.8	32.1	32.9	32.6	31.5

Source: Company, Emkay Research

**RECOMMENDATION HISTORY - DETAILS**

Date	Closing Price (INR)	TP (INR)	Rating	Analyst
08-Sep-23	697	780	Buy	Dharmesh Shah
07-Aug-23	629	780	Buy	Dharmesh Shah
04-Jul-23	670	800	Buy	Dharmesh Shah

Source: Company, Emkay Research

**RECOMMENDATION HISTORY - TREND**



Source: Company, Bloomberg, Emkay Research



**GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):**

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India. EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of BSE Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX), Multi Commodity Exchange of India Ltd (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) (hereinafter referred to be as "Stock Exchange(s)"). EGFSL along with its [affiliates] offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. [www.emkayglobal.com](http://www.emkayglobal.com).

EGFSL is registered as Research Analyst with the Securities and Exchange Board of India ("SEBI") bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014. EGFSL hereby declares that it has not defaulted with any Stock Exchange nor its activities were suspended by any Stock Exchange with whom it is registered in last five years. However, SEBI and Stock Exchanges had conducted their routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to its existing clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the clients simultaneously, not all clients may receive this report at the same time. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient.

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. EGFSL may have issued or may issue other reports (on technical or fundamental analysis basis) of the same subject company that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Users of this report may visit [www.emkayglobal.com](http://www.emkayglobal.com) to view all Research Reports of EGFSL. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of EGFSL; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its affiliates. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

This report has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research report relating to any issuer/subject company.

Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets.

**Disclaimer for U.S. persons only:** Research report is a product of Emkay Global Financial Services Ltd., under Marco Polo Securities 15a6 chaperone service, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors. Emkay Global Financial Services Ltd. has entered into a chaperoning agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo"). Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.



**RESTRICTIONS ON DISTRIBUTION**

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation. Except otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be distributed in Canada or used by private customers in United Kingdom.

**ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)**

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associated persons<sup>1</sup> may have served as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate may have Financial Interests<sup>2</sup> in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

<sup>1</sup> An associated person is defined as (i) who reports directly or indirectly to such a research analyst in connection with the preparation of the reports; or (ii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

<sup>2</sup> Financial Interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

**COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):**

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report:-

- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her associate/relative's may have Financial Interest/proprietary positions in the securities recommended in this report as of November 10, 2023
- EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Report  
**Disclosure of previous investment recommendation produced:**
- EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's may have material conflict of interest in the securities recommended in this report as of November 10, 2023
- EGFSL, its affiliates and Research Analyst or his/her associate/relative's may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the November 10, 2023
- EGFSL or its associates may have managed or co-managed public offering of securities for the subject company in the past twelve months.
- EGFSL, its affiliates and Research Analyst or his/her associate may have received compensation in whatever form including compensation for investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
- EGFSL, its affiliates and/or and Research Analyst or his/her associate may have received any compensation or other benefits from the subject company or third party in connection with this research report.

**Emkay Rating Distribution**

Ratings	Expected Return within the next 12-18 months.
<b>BUY</b>	Over 15%
<b>HOLD</b>	Between -5% to 15%
<b>SELL</b>	Below -5%

**Emkay Global Financial Services Ltd.**

CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India

Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkayglobal.com

**OTHER DISCLAIMERS AND DISCLOSURES:****Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) -:**

EGFSL or its associates may have financial interest in the subject company.

Research Analyst or his/her associate/relative's may have financial interest in the subject company.

EGFSL or its associates and Research Analyst or his/her associate/ relative's may have material conflict of interest in the subject company. The research Analyst or research entity (EGFSL) have not been engaged in market making activity for the subject company.

EGFSL or its associates may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst or his/her associate/relatives may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst may have served as an officer, director or employee of the subject company.

EGFSL or its affiliates may have received any compensation including for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. . Emkay may have issued or may issue other reports that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Emkay Investors may visit [www.emkayglobal.com](http://www.emkayglobal.com) to view all Research Reports. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of Emkay; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. EGFSL or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months. EGFSL or its associates may have received any compensation or other benefits from the Subject Company or third party in connection with the research report. EGFSL or its associates may have received compensation from the subject company in the past twelve months. Subject Company may have been client of EGFSL or its affiliates during twelve months preceding the date of distribution of the research report and EGFSL or its affiliates may have co-managed public offering of securities for the subject company in the past twelve months.